Skip to main content
Home > Conferences > BioEquity Europe > Dates, Location & Schedules > Presenting Companies Schedule
BioCentury Conference Center

Bio€quity Europe 2016 Conference Agenda

Monday, May 9
19:00 - 21:00 Welcome Networking Reception at Scandic Copenhagen Hotel - Lounge Bar

Badge Pickup is open 18:30-21:00.

Vester Soegade 6
1601 Copenhagen, Denmark

Tuesday, May 10
07:45 Registration Opens and Light Breakfast (Conference Foyer)
09:00 - 09:30 Welcome and Official Greeting from the Organizers and Regional Hosts

Anna Chrisman, Group Managing Director, EBD Group
David Flores, Co-Founder, President & CEO, BioCentury
Dr. Søren Møller, Managing Partner, Novo Seeds
David Thomas, Director, Industry Research & Analysis, Biotechnology Innovation Organization (BIO)
09:30 - 10:30 Opening Plenary - The BioEquity Europe Face-Off - Lost in Translation

BioCentury is finding a fundamental disconnect in Europe. Pools of investment capital are forming around academic science, even as the money needed to get those discoveries into and through the clinic continues to lag. At the scene-setting Bio€quity Europe Face-Off, top Editors Susan Schaeffer of BioCentury and Simone Fishburn of BioCentury Innovations document this conundrum and debate with the audience whether it could thwart European biotech's global ambitions.

With Response From:
Roel Bulthuis, Head, MS Ventures Anne Marden, Portfolio Manager for Global Healthcare Fund, JPMorgan Antoine Papiernik, Managing Partner, Sofinnova
10:30 - 11:00 Coffee Break
11:00 - 12:00

Plenary 1 - Global Venture Scorecard - Hard Facts From U.S. VCs (Room 1)

What's Needed in Europe to Get More U.S. Investor Representation? Over the past several years, Bio€quity Europe has addressed whether European science is competitive on a global landscape and whether European companies have what it takes to play in the Champion's League for capital. This year, we examine both themes from the perspective of U.S. investors. This Bio€quity plenary session brings together U.S. managers who control more than $30 billion in capital to share notes on what is required to get more U.S. investor representation in Europe. And what's needed for them to invest in European biotechs. Plus case studies on successful cross-border investment.

Moderator: Paul Hadden, Managing Director, HealthCare Royalty Partners
Chau Khuong, Private Equity Partner, OrbiMed
Dr. Ernest Loumaye, Co-Founder and CEO, ObsEva S.A.
Ed Mathers, Partner, NEA
Dr. Kush Parmar, Managing Partner, 5AM Ventures
Kurt von Emster, Managing Partner, Abingworth

Plenary 2 - Old Schools, New Seeds at the Academia - Industry Interface (Room 2)

One year ago, BioCentury's annual review of European biotech finance asked whether innovation is "underfed" in Europe. Today, the "translational" soil is promising a good harvest, with a crop of new seed funds promising to commercialize discoveries from Europe's academic centers. At Bio€quity Europe 2016, architects of these new funds identify what's driving the influx of new money. Has the science become more investable? And what will it take beyond the money to turn these concepts into products for patients?

Moderators: Dr. Tomas Landh, Senior Principal Scientist Innovation Sourcing, Novo Nordisk
and
John Hallinan, CBO, MassBIO
Dr. Laurent Audoly, Managing Partner, Pierre Fabre Fund for Innovation
Dr. Dani Bach, Partner, Imperial Innovations
Dr. Keith Blundy, CEO, Cancer Research Technology
Dr. Johan Kördel, Senior Partner, Lundbeckfond Ventures
Dr. Giovanni Mariggi, Partner, Medicxi Ventures
Graziano Seghezzi, Partner, Sofinnova Partners
12:00 - 14:00 Lunch and Networking Time (Hotel Restaurant)
 

Presentation Rooms

Room 1 Room 2 Room 3 Room 4
14:00 - 14:20 Molecular Partners AG (SIX:MOLN) Acacia Pharma Group plc CEO Boot camp #7
Managing and Hiring for Success - What's the Best CEO Phenotype?

(14:00 - 15:15) (Room 3)

CEOs are responsible not only for company leadership but also for recruiting and hiring key team members. Transitioning from big pharma/biotech or academia to a small biotech can be a challenge. How can the CEO pick those who will succeed in the biotech atmosphere, particularly a start-up? How can a CEO ensure their success through the hiring process? The CEO boot camp will evaluate what phenotypes work best for biotech, what strategies have worked and what strategies should be avoided …

Moderator: Carole Nuechterlein, Partner, Roche Venture Fund
Dr. Martin Bonde, CEO, Vaccibody A/S
Tim Dyer, CEO, Addex Therapeutics Ltd.
Dr. Christian Elling, Partner, Lundbeckfond Emerge
Elias Papatheodorou, CEO, Genkyotex SA
Sarah Shackleton, Partner, Abingworth
Next Wave Companies (CAN/Ab platforms)
14:00-14:10
    HiFiBiO S.A.S.
14:10-14:20
     NBE Therapeutics AG
14:20-14:30
     Amal Therapeutics S.A.
14:30-14:40
     Inthera Bioscience AG
14:40-14:50
     Invectys S.A.
14:50-15:00
    IO Biotech ApS
15:00-15:10
     Reapplix ApS
15:10-15:20
     eTheRNA N.V.
15:30-15:40
     Abionic SA
15:40-15:50
     SurgiMAb S.A.S
15:50-16:00
     Xbrane Bioscience AB
     (SSE:XBRANE)
16:00-16:10
    RSPR Pharma AB
16:10-16:20
     Acousia Therapeutics
     GmbH
16:20-16:30
     Enterprise Therapeutics
     Ltd.
16:30-16:40
     InSphero AG

20 Minute BREAK

17:00-17:10
    Calypso Biotech S.A.
17:10-17:20
    Follicum AB
    (AktieTorget:FOLLI)
17:20-17:30
    Atriva Therapeutics
    GmbH
17:30-17:40
    Euroscreen S.A.
17:40-17:50
    Edinburgh Molecular
    Imaging Ltd.
17:50-18:00
    Omeicos Therapeutics
    GmbH
18:00-18:10
    Gadeta B.V.

14:20 - 14:40

Apitope International N.V. OxThera AB
14:40 - 15:00 Curetis N.V. (Euronext:CURE) ObsEva S.A.
15:00 - 15:20 Neovacs S.A. (Euronext:ALNEV) Santhera Pharmaceuticals Holding AG (SIX:SANN)
15:20 - 15:40 Nanobiotix S.A. (Euronext:NANO) Merus B.V.

Big Pharma / VC Worlds - An Evolving Relationship
(15:30 - 16:45) (Room 3)

Pharma and big biotech are taking new approaches to accessing early stage investments and technology, which have implications for young biotechs. This workshop will explore the dynamic between big pharma and the venture community and explore how young companies can strategically position their growth and interactions with both groups. In addition, it will examine whether corporate VCs have the assets and the ability to fill a void in the private space that has been created by an exodus of crossover investors.

Moderator: Dr. Frank Kalkbrenner, Managing Director, Boehringer Ingelheim Venture Fund
Dr. Jeanne Bolger, VP of Venture Investments, Johnson & Johnson
Dr. Vincent Brichard, Venture Partner, LSP
Dr. Bernard Davitian, VP and Managing Director, Sanofi-Genzyme BioVentures
Arthur Franken, Partner, Gilde Healthcare
Dr. Hakan Goker, Senior Investment Director, MS Ventures
15:40 - 16:00 Cantargia AB (SSE:CANTA) Selvita S.A. (Warsaw:SLV)
16:00 - 16:20 F-star Biotechnology Ltd. Mission Therapeutics Ltd.
16:20 - 16:40 SynAffix B.V. Genkyotex S.A.
16:40 - 17:00 Arsanis Inc. Apogenix AG
17:00 - 17:20 Alligator Bioscience AB Piqur Therapeutics AG Kiadis Pharma N.V. (Euronext:KDS)
17:20 - 17:40 Oncopeptides AB Zealand Pharma A/S (CSE:ZEAL) MiNA Therapeutics Ltd.
17:40 - 18:00 4SC AG (Xetra:VSC) Autifony Therapeutics Ltd. Promethera Biosciences S.A.
18:15 - 18:45 Transportation to Networking Reception and Dinner
19:00 Networking Reception and Dinner
Toldboden - Nordre Toldbod 24
1259 København K
Denmark

Hosted by The Regional Host Sponsors
2016 Regional Host Sponsors
Wednesday, May 11
07:45 Registration Opens and Light Breakfast (Conference Foyer)
 

Presentation Rooms

Room 1 Room 2 Room 3 Room 4
09:00 - 09:20 Vaximm AG Atlantic Healthcare plc Capital Access - Global vs. Local
(09:00-10:00) (Room 3)

Following discussions over the past two years on best practices to access growth capital, this Bio€quity Europe panel discusses listing strategies for biotech companies. What types of companies can cross the pond for a U.S. listing? Are US investors' criteria different from European investors? Are there situations when it is better to list locally with an eye to expand your listing to a U.S. exchange in the future?

Moderator: James Gubbins, Partner, Covington
Dr. Gil Bar-Nahum, Managing Director in the Global Healthcare Investment Banking Group, Jefferies
Dr. Florian Fischer, CFO, Affimed N.V.
Alex Ibrahim, Head of International Capital Markets, NYSE
Dr. Jörg Neermann, Partner, LSP
Next Wave Companies
(ID & NEURO)
9:00-9:10
    Adenium Biotech ApS
9:10-9:20
    Avilex Pharma ApS
9:20-9:30
    Treeway B.V.
9:30-9:40
    Prexton Therapeutics
    S.A.
9:40-9:50
    Evaxion Biotech
9:50-10:00
    TocopheRx Inc.
10:00-10:10
    Pcovery ApS
11:10-11:20
    RDD Pharma Ltd.
11:20-11:30
    Micreos B.V.
11:30-11:40
    Destiny Pharma Ltd.
11:40-11:50
    InflaRX GmbH
11:50-12:00
    BiOrion Technologies
    B.V.
12:00-12:10
    Lytix Biopharma A/S
12:10-12:20
    Moebius Medical Ltd.
12:20-12:30
    CellProthera S.A.S.
12:30-12:40
    Mint Solutions
09:20 - 09:40 Karus Therapeutics Ltd. Enterome Bioscience S.A.
09:40 - 10:00 Immunicum AB (SSE:IMMU) Catalyst Biosciences Inc. (NASDAQ:CBIO)
10:00 - 10:20 Kesios Therapeutics Ltd. ReNeuron Group plc (LSE:RENE)

European Pre-Seed Showcase (10:15-11:15) (Room 3)

Selected Pre-Seed Companies present to a diverse panel of Bio€quity Europe 'judges' who provide high level feedback on their business plan, presentation and overall strategy.

Judges:
Dr. Karen Bernstein, Chairman & Co-Founder, BioCentury
Kate Bingham, Partner, SV Life Sciences
Dr. Declan Jones, Neuroscience Scientific Innovation, Johnson & Johnson
Dr. Allan Marchington, Senior Advisor, Apposite Capital

Antagonis Biotherapeutics GmbH
AntibioTx ApS
Biopetrolia AB
GlioPharma ApS
Immunitrack
NMD Pharma ApS

10:20 - 10:40 Nordic Nanovector ASA (OSE:NANO) Verona Pharma plc (LSE:VRP; Xetra:I9S)
10:40 - 11:00 Affimed N.V. (NASDAQ:AFMD) Galecto Biotech AB
11:00 - 11:20 AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) PCI Biotech Holding ASA (OSE:PCIB)
11:20 - 11:40 Actinogen Medical Ltd. (ASX:ACW) Motif Bio plc (LSE:MTFB) Global Ambition - Case Studies
(11:30-12:30) (Room 3)

Against the backdrop of Bio€quity's 'Global Ambitions' theme, this panel asks how VCs should think about creating companies and funding broader ambition. Does the scale of a company's ambition correlate with the scale of the outcome from an investor standpoint?

Moderator: Dr. Richard Soll, Senior Vice President, International Discovery Service Unit, WuXi AppTec
Dr. Carl-Johan Dalsgaard, CEO, RSPR Pharma AB
Soren Lemonius, Partner, Sunstone
Dr. Hans Schambye, CEO, Galecto Biotech AB
Dr. Nathalie ter Wengel, European Head Global Scouting External R&D Innovation, Pfizer
11:40 - 12:00 Probiodrug AG (Euronext:PBD) Faron Pharmaceuticals Oy (LSE:FARN)
12:00 - 12:20 Canbex Therapeutics Ltd. Strongbridge Biopharma plc (NASDAQ:SBBP)
12:20 - 12:40 Cevec Pharmaceuticals GmbH Paion AG (XE:PA8)
12:30 - 14:00 Lunch and Networking Time
14:00 - 14:20 Symic Biomedical Inc. Camurus AB (SSE:CAMX)    
14:20 - 14:40 Targovax A/S  
14:40 - 15:00 Cerenis Therapeutics S.A. (Euronext:CEREN) Oncology Venture ApS
15:00 - 15:20 Epigenomics AG (Xetra:ECX) Serodus ASA (OSE:SER)
15:20 - 15:40    
15:40 - 16:00
16:00 Networking Closing Reception